You are here

bladder cancer

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

Fierce Pharma

clinical trials

Flag link:

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

Fierce Pharma

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Has Merck Lucked Into A $10 Billion Drug?

Has Merck Lucked Into A $10 Billion Drug?

Forbes

non-small cell lung cancer

Flag link:

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

Endpoints

clinical trials

Flag link:

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Fierce Pharma

Flag link:

AstraZeneca's New Drug: Too Little, Too Late?

AstraZeneca's New Drug: Too Little, Too Late?

Seeking Alpha

Flag link:

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Fierce Pharma

Flag link:

Merck KGaA, Pfizer get priority review for bladder cancer drug

Merck KGaA, Pfizer get priority review for bladder cancer drug

Yahoo/Reuters

Flag link:

Checkpoint inhibitors set to face off in bladder cancer

Checkpoint inhibitors set to face off in bladder cancer

BioPharma Dive

Bristol-Myers Squibb

Flag link:

FDA approves Bristol-Myers' Opdivo for bladder cancer

FDA approves Bristol-Myers' Opdivo for bladder cancer

Yahoo/Reuters

Bristol-Myers Squibb

Flag link:

Taris Biomedical closes enrollment in phase Ib trial for drug-device combo

Taris Biomedical closes enrollment in phase Ib trial for drug-device combo

Mass Device

drug-device combos

Flag link:

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Endpoints

Flag link:

Heat Biologics stock active on heels of lung, bladder cancer results

Heat Biologics stock active on heels of lung, bladder cancer results

Bizjournals.com

Flag link:

Bristol’s Opdivo Has One Eye on Advanced Bladder Cancer

Bristol’s Opdivo Has One Eye on Advanced Bladder Cancer

Market Realist

Bristol-Myers Squibb

Flag link:

Sanofi Shuts Down Bladder Cancer Drug Production: Inevitable Drug Shortage To Harm Patients

Sanofi Shuts Down Bladder Cancer Drug Production: Inevitable Drug Shortage To Harm Patients

Forbes

Flag link:

Merck's Keytruda succeeds in key bladder cancer trial

Merck's Keytruda succeeds in key bladder cancer trial

Yahoo/Reuters

clinical trials

Flag link:

Merck's Keytruda posts 24% response rate in PhII bladder cancer study

Merck's Keytruda posts 24% response rate in PhII bladder cancer study

Fierce Pharma

Flag link:

Bristol-Myers Squibb Co Wins a Sixth Breakthrough Tag for Opdivo

Bristol-Myers Squibb Co Wins a Sixth Breakthrough Tag for Opdivo

Bidness, ETC

Bristol-Myers Squibb

breakthrough therapies

Flag link:

Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy designation

Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy designation

Marketwatch

Bristol-Myers Squibb

breakthrough therapies

Flag link: